The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent. / Aagaard, Susanne; Hjortdal, Vibeke E; Barker, John H.

In: A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, No. 109, 2003, p. 102-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Aagaard, S, Hjortdal, VE & Barker, JH 2003, 'The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent', A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, no. 109, pp. 102-7.

APA

Aagaard, S., Hjortdal, V. E., & Barker, J. H. (2003). The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent. A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, (109), 102-7.

Vancouver

Aagaard S, Hjortdal VE, Barker JH. The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent. A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica. 2003;(109):102-7.

Author

Aagaard, Susanne ; Hjortdal, Vibeke E ; Barker, John H. / The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent. In: A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica. 2003 ; No. 109. pp. 102-7.

Bibtex

@article{8381a85af57c4671b74da18371b7991d,

title = "The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent",

abstract = "Tissue factor pathway inhibitor (TFPI) acts by complexing with tissue factor and factors VIIa and Xa to retard the extrinsic pathway of the coagulative process. The present study was designed to assess the antithrombotic properties of topically applied TFPI in a model of rabbit arterial thrombosis. A standardised, thrombogenic end-to-end anastomosis was made on the central ear artery. The anastomotic site was irrigated with vehicle (control, n = 5), TFPI 4 micrograms/ml (n = 8), TFPI 40 micrograms/ml (n = 8), or heparin 100 IE/ml (n = 7). The growing thrombus was observed under a stereo microscope. The image was displayed on a video monitor and recorded for analysis using computer assisted planimetry. Topical application of TFPI in either concentration or heparin did not change maximal thrombus size, mean thrombus size, or time to maximal thrombus size significantly when compared to the contralateral vehicle-treated ear. Significant anastomotic bleeding was observed in vessels treated with TFPI 40 micrograms/ml (p < 0.05).",

keywords = "Administration, Topical, Animals, Anticoagulants/administration & dosage, Blood Vessels/injuries, Lipoproteins/administration & dosage, Male, Rabbits, Thromboplastin/antagonists & inhibitors, Thrombosis/drug therapy",

author = "Susanne Aagaard and Hjortdal, {Vibeke E} and Barker, {John H}",

year = "2003",

language = "English",

pages = "102--7",

journal = "A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica",

issn = "0903-4641",

publisher = "Wiley Online",

number = "109",

}

RIS

TY - JOUR

T1 - The efficacy of tissue factor pathway inhibitor (TFPI) as topically applied antithrombotic agent

AU - Aagaard, Susanne

AU - Hjortdal, Vibeke E

AU - Barker, John H

PY - 2003

Y1 - 2003

N2 - Tissue factor pathway inhibitor (TFPI) acts by complexing with tissue factor and factors VIIa and Xa to retard the extrinsic pathway of the coagulative process. The present study was designed to assess the antithrombotic properties of topically applied TFPI in a model of rabbit arterial thrombosis. A standardised, thrombogenic end-to-end anastomosis was made on the central ear artery. The anastomotic site was irrigated with vehicle (control, n = 5), TFPI 4 micrograms/ml (n = 8), TFPI 40 micrograms/ml (n = 8), or heparin 100 IE/ml (n = 7). The growing thrombus was observed under a stereo microscope. The image was displayed on a video monitor and recorded for analysis using computer assisted planimetry. Topical application of TFPI in either concentration or heparin did not change maximal thrombus size, mean thrombus size, or time to maximal thrombus size significantly when compared to the contralateral vehicle-treated ear. Significant anastomotic bleeding was observed in vessels treated with TFPI 40 micrograms/ml (p < 0.05).

AB - Tissue factor pathway inhibitor (TFPI) acts by complexing with tissue factor and factors VIIa and Xa to retard the extrinsic pathway of the coagulative process. The present study was designed to assess the antithrombotic properties of topically applied TFPI in a model of rabbit arterial thrombosis. A standardised, thrombogenic end-to-end anastomosis was made on the central ear artery. The anastomotic site was irrigated with vehicle (control, n = 5), TFPI 4 micrograms/ml (n = 8), TFPI 40 micrograms/ml (n = 8), or heparin 100 IE/ml (n = 7). The growing thrombus was observed under a stereo microscope. The image was displayed on a video monitor and recorded for analysis using computer assisted planimetry. Topical application of TFPI in either concentration or heparin did not change maximal thrombus size, mean thrombus size, or time to maximal thrombus size significantly when compared to the contralateral vehicle-treated ear. Significant anastomotic bleeding was observed in vessels treated with TFPI 40 micrograms/ml (p < 0.05).

KW - Administration, Topical

KW - Animals

KW - Anticoagulants/administration & dosage

KW - Blood Vessels/injuries

KW - Lipoproteins/administration & dosage

KW - Male

KW - Rabbits

KW - Thromboplastin/antagonists & inhibitors

KW - Thrombosis/drug therapy

M3 - Journal article

C2 - 12874959

SP - 102

EP - 107

JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

SN - 0903-4641

IS - 109

ER -

ID: 243519286